Drug news
Nypta (Zeltia/Noscira) fails Alzheimers Disease study
Zeltia/ Noscira announces that the primary cognitive endpoint and two of the secondary endpoints were not met in the 26-week ARGO Phase IIb trial involving Nypta (tideglusib). This study evaluated the efficacy of tideglusib versus placebo plus standard of care for the treatment of mild-to-moderate Alzheimers Disease. No decision regarding future development has yet been taken as Zeltia says pending analyses of the other secondary end-points, subpopulations, biomarkers and a magnetic resonance image substudy will be completed in the coming weeks,
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.